|
|
|
|
|
A
skeletal disorder characterized by compromised bone strength predisposing
to an increased risk of fracture. |
|
|
|
NIH
Consensus Statement 2000 |
|
|
|
|
|
|
Bone mineral density (BMD) 2.5 standard
deviations below the mean bone mineral density of healthy, young, white
women |
|
(T-score of -2.5) or |
|
Fracture in the absence of significant trauma in
a postmenopausal woman |
|
|
|
World
Health Organization working group 1992 |
|
|
|
|
Osteopenia – BMD 1 to 2.5 standard deviations
below the mean (T-score -1.0 to -2.5) |
|
Unclear clinical value – wide range of fracture
risk found among women in this category |
|
|
|
|
|
|
Central DEXA scan for bone mineral density, BUT true “gold standard” is
fracture/fracture rates for public health purposes. |
|
|
|
|
Rates vary among racial and ethnic groups |
|
Data is best established for Caucasian females |
|
Limited data available regarding osteoporosis
and fracture rates in American Indian and Alaska Natives |
|
Data suggests that they are at least as great a
problem as for the general population |
|
|
|
|
National
Osteoporosis Risk Assessment (NORA) |
|
Study
of peripheral osteoporosis |
|
screening |
|
1708
“Native American” women – risk |
|
of
fracture over life of the study was the |
|
same as that of “white” women |
|
|
|
|
Small
study in the Sac and Fox Nation of Oklahoma |
|
Lower
BMD in postmenopausal |
|
women as measured by central |
|
DEXA
than that reported for “white” |
|
women |
|
|
|
The
effect of aging on bone mineral metabolism and bone mass in Native American
Women, J Am Geriatr Soci 1998; 46: |
|
1418-22 |
|
|
|
|
|
|
White 1.00 (referant) |
|
African American 0.54 (0.41-0.72) |
|
Native American 0.89 (0.59-1.34) |
|
Hispanic 0.91 (0.72-1.15) |
|
Asian 0.41 (0.21-1.79) |
|
|
|
|
|
|
|
|
Review
of hip fractures at Alaska Native Medical Center |
|
|
|
Higher
fracture rates than reported for white US women during the periods of
1979-1989 and 1996-1999 |
|
|
|
Incidence of hip fracture in Alaska Inuit people, Alaska Med; 2001,
43: 2-5 |
|
|
|
|
|
|
Low calcium intake |
|
Sedentary lifestyle |
|
Issues with body mass index |
|
Smoking |
|
|
|
Osteoporosis in Native Americans, IHS Provider 2002; |
|
94: 94-101 |
|
|
|
|
|
|
|
Skeletal |
|
History of maternal hip fracture (RR=2.0) |
|
Age, per 5 year (RR=1.5) |
|
Current cortisone use (RR=1.57) |
|
Current smoking (RR=1.14 - 2.1) |
|
Low Body Mass Index (BMI >30 has RR 0.16 of
having osteoporosis) |
|
Race (African-American RR= 0.54) |
|
|
|
|
|
|
|
|
Use of anticonvulsant drugs (RR=2.8) |
|
Serious long-term conditions thought to increase
fracture risk such as hyperthyroidism or malabsorption |
|
|
|
|
|
Non-skeletal |
|
Poor vision (RR=1.5) |
|
Inability to rise from chair (RR=2.1) |
|
Benzodiazapine use (RR=1.6) |
|
Fall in the previous year (RR=1.6) |
|
Self-rated health status of fair/poor (RR=1.79) |
|
|
|
|
|
|
|
|
Risk Factor Mean RR-OR |
|
Muscle weakness 4.4 |
|
History of falls 3.0 |
|
Gait deficit 2.9 |
|
Balance deficit 2.9 |
|
Use assistive device 2.6 |
|
Visual deficit 2.5 |
|
|
|
From:
Guidelines for the Prevention of Falls in Older Persons, Journal of
the American Geriatric Society 49:664-672, 2001 |
|
|
|
|
All older persons who are under the care of a
health professional (or their caregivers) should be asked at least once a
year about falls. |
|
All older persons who report a single fall
should be observed as they stand up from a chair without using their arms,
walk several paces, and return (i.e., the “Get Up and Go Test”). Those demonstrating no difficulty or
unsteadiness need no further assessment. |
|
|
|
From:
Guidelines for the Prevention of Falls in Older Persons, Journal of
the American Geriatric Society 49:664-672, 2001 |
|
|
|
|
|
|
Persons who have difficulty or demonstrate
unsteadiness performing this test require further assessment. |
|
|
|
From:
Guidelines for the Prevention of Falls in Older Persons, Journal of
the American Geriatric Society 49:664-672, 2001 |
|
|
|
|
|
|
|
|
Older persons who should have a fall evaluation
performed: |
|
Present for medical attention because |
|
of a
fall |
|
Report recurrent falls in the past year |
|
Demonstrate abnormalities of gait and/or |
|
balance. |
|
|
|
|
|
|
Fall Evaluation |
|
Should be performed by a clinician with
appropriate skills and experience |
|
May necessitate referral to a specialist (e.g.,
geriatrician). |
|
|
|
|
|
|
|
Fall evaluation |
|
Assessment that includes the following: |
|
A
history of fall circumstances |
|
Medications |
|
Acute or chronic medical problems |
|
Mobility levels |
|
Examination of vision |
|
Examination of gait, balance and lower extremity joint |
|
function |
|
|
|
|
|
|
|
|
Examination of basic neurological function |
|
Mental
status |
|
Muscle
strength |
|
Lower
extremity peripheral nerves |
|
Proprioception |
|
Reflexes |
|
Tests of
cortical, extrapyramidal, and |
|
cerebellar functions |
|
|
|
|
|
|
|
|
Assessment of basic cardiovascular status
including heart rate and rhythm |
|
Postural pulse and blood pressure |
|
If
appropriate, heart rate and blood |
|
pressure
responses to carotid |
|
sinus
stimulation. |
|
|
|
|
|
|
Muscle strengthening and balance retraining |
|
Professional home hazard assessment and
modification |
|
Stopping or reducing psychotropic medication |
|
|
|
NEJM 348: 42-9, 2003; NEJM 331: 821-7, 1994 |
|
Note:
Optimal duration or intensity of these approaches have not been defined |
|
|
|
|
Hip protectors reduce the risk of hip fracture
for elderly individuals who live in nursing homes and residential care
facilities, as well as those in supported living at home |
|
The generalization of the results beyond this
high risk population is unknown |
|
|
|
|
One study found that 41 patients would need to
be offered treatment with a hip protector to prevent one hip fracture over
the course of one year (NEJM 343: 1506-13; 2000) |
|
Hip protectors may be a reasonable and
cost-effective option for patients at high risk of falls. |
|
|
|
|
Randomized controlled trial among women over 70
living in the community found that hip protectors offered no significant
reduction in the risk of hip fracture (Birks -Osteoporos Int 2004, Mar 3) |
|
Compliance rates were quite low (about 30%) |
|
Need for more acceptable, easy-to-use devices
that can protect fragile bones |
|
|
|
|
|
|
|
Bisphosphonates |
|
Alendronate |
|
Risedronate |
|
Calcium + Vitamin D |
|
Calcitonin |
|
Estrogen |
|
Selective estrogen receptor modulator
(Raloxifene) |
|
Teriparatide (recombinant human parathyroid
hormone) |
|
|
|
|
|
|
|
POEM:
Patient Oriented Evidence that Matters |
|
Hip and Vertebral Fractures |
|
DOE:
Disease Oriented Evidence |
|
Bone Density |
|
|
|
|
|
|
In postmenopausal women with osteoporosis does
alendronate compared to placebo reduce hip and vertebral fractures? |
|
Answer:
Good evidence based on randomized, controlled trials… |
|
|
|
|
|
|
|
|
|
|
|
|
“Esophagitis, esophageal ulcers and esophageal
erosions, occasionally with bleeding and rarely followed by esophageal
stricture or perforation, have been reported in patients receiving
treatment with alendronate sodium. In some cases these have been severe and
required hospitalization.”3 |
|
One RCT found that when taken correctly, there
was no significant difference in esophagitis with alendronate versus
placebo4 |
|
From the SG:
“appears to be safe and effective for up to 10 years.” |
|
|
|
|
|
|
Calcium and Vitamin D |
|
In mobile elderly women in nursing homes does
Calcium and Vit D compared to placebo reduce hip fracture? |
|
Yes, quite impressively. |
|
The NNT at 3 years to prevent one hip fracture
in this population is 25. |
|
NNT at 18 months to prevent one hip fracture is
50. |
|
|
|
|
|
|
|
|
|
|
Does screening for osteoporosis using risk
factor assessment or bone density testing reduce fractures? |
|
USPSTF answer:
“We identified no studies about the effectiveness of screening in
reducing osteoporotic fractures.” |
|
Therefore:
“Recommendations about screening need to rely on evidence that risk
factor assessment or bone density testing can adequately identify women who
could ultimately benefit from treatment.” |
|
|
|
|
Osteoporosis Risk Assessment Instrument (ORAI)6
is one of two validated risk factor assessment tools given a “good”
quality rating by the USPSTF5 |
|
95 % sensitive and 41 % specific for detecting
hip or lumbar spine BMD T-score <-2.5. |
|
|
|
|
|
|
|
DXA (dual energy x-ray absorptiometry) |
|
Hip |
|
Spine |
|
Peripheral Densitometry (DXA or SXA) |
|
Distal radius |
|
Calcaneus |
|
Finger |
|
Quantitative Computed Tomography |
|
Spine |
|
Quantitative Ultrasound |
|
Calcaneus |
|
Tibia |
|
|
|
|
|
|
|
|
1996 BMJ meta-analysis7 showed all
measuring sites had similar predictive abilities for fracture. |
|
RR 1.5 (CI 1.4-1.6) for 1 SD decrease in BMD for
age (Z-score) except: |
|
Measurement at spine for vertebral
fractures: RR 2.3 (CI 1.9-2.8) |
|
Measurement at hip for hip fractures: RR 2.6 (CI 2.0-3.5) |
|
|
|
|
|
As stated by the USPSTF: “the probability of receiving a
diagnosis of osteoporosis depends on the choice of test and site.” |
|
USPSTF: “the likelihood of receiving a diagnosis
of osteoporosis also depends on the number of sites tested.” |
|
National Osteoporosis Risk Assessment8: |
|
the
probability of having osteoporosis varied from 3.4% (heel ultrasound) to
13.5% (finger DXA) depending on site tested and method of testing. |
|
Odds of osteoporosis by site tested: Heel ultrasound OR 0.79, DXA at forearm
or finger OR 2.86, 4.82. |
|
|
|
|
Again from the USPSTF: “DXA is considered the gold standard because it is the most
extensively validated test against fracture outcomes.” |
|
Randomized, controlled trials, such as FIT, use
femoral neck DXA to identify patients with osteoporosis that might benefit
from therapy. |
|
|
|
|
|
|
|
|
|
EPIDOS 9: 1996 prospective study of 5662 elderly women with 115 hip
fractures in average follow-up of two years |
|
Patients had calcaneal ultrasound (Lunar Corp.)
and femoral DXA |
|
Relative risk of hip fracture for 1 SD reduction |
|
in ultrasound attenuation at heel 2.0 (CI
1.6-2.4) |
|
in hip BMD 1.9 (CI 1.6-2.4) |
|
Author conclusions: Calcaneal ultrasound
“predicts the risk of hip fracture as efficiently as DXA.” |
|
|
|
|
|
The 1997 Study of Osteoporotic Fractures
Research Group10 followed 6189 women over 65 for an average of 2
years |
|
54 hip fractures |
|
Calcaneal quantitative ultrasound (Walker-Sonix)
and hip and calcaneal DXA were performed |
|
Relative risk of hip fracture for 1 SD reduction |
|
In heel ultrasound attenuation 2.0 (1.5-2.7) |
|
In hip BMD 2.6 (1.9-3.8) |
|
Author conclusion: “the strength for the association between BUA and fracture is
similar to that observed with bone mineral density.” |
|
|
|
|
|
200 women age 60-69 in British general practice
had DXA and heel ultrasound (Sahara) and risk factor screening |
|
Ultrasound T-score <1.7 SD (lowest quartile)
compared to a “gold standard” of osteoporosis on DXA yielded |
|
sensitivity of 71% and specificity of 83% |
|
PPV of 45% and NPV of 94% |
|
16.3 % of patients had osteoporosis |
|
Including risk factor screening |
|
Sensitivity 90%, specificity 38% |
|
PPV 22%, NPV 95% |
|
|
|
|
|
|
|
|
Why? |
|
It will help your patients “live long and live
well.” |
|
October 2004:
“The intent of this Surgeon General’s Report is to serve as a
catalyst for the development of a public health approach to promoting bone
health.” |
|
The Surgeon General urges: “implement a
comprehensive, systems-based approach to promoting bone health.” |
|
2002-2011 Decade of Bone and Joint |
|
Healthy People 2010 |
|
“reduce the number of individuals with
osteoporosis and hip fractures…” |
|
HEDIS, GPRA |
|
|
|
|
|
|
|
|
|
Avoid pitfalls |
|
No screening program |
|
Not identifying and treating the highest risk
individuals |
|
Not appropriately utilizing cost/effort |
|
Focusing on unproven technologies if DEXA is
available |
|
Remember the pyramid |
|
|
|
|
|
|
|
Pitfall #1:
No screening program |
|
|
|
|
|
|
|
|
Pitfall #2:
Not identifying and treating the highest-risk individuals |
|
Consider secondary osteoporosis (e.g. ESRD,
rheumatoid arthritis, steroid use) |
|
Treat patients with fragility fractures (the
“sentinel event”) |
|
Only 22-24% of patients with fractures treated
in two recent studies |
|
A recent controlled trial showed improved
treatment after fracture with faxed reminders to physicians (still only
40%). |
|
Do not delay treatment for imaging |
|
Screen women over 75 and frail elderly first |
|
|
|
|
|
Pitfall #3:
Not appropriately utilizing cost and effort |
|
Do not prioritize screening young,
well-nourished, otherwise healthy, women. |
|
Initiate population screening no earlier than 65
years of age |
|
|
|
|
|
|
|
|
Pitfall #4:
Focusing on unproven technologies if DEXA is available |
|
|
|
|
|
|
|
|
Pitfall #5:
Remember the Pyramid! (and don’t invert it.) |
|
Use Calcium |
|
NNT in some populations 25 |
|
|
|
|
|
|
|
|
|
|
Hans D, et al.
Ultrasonographic heel measurements to predict hip fracture in
elderly women: the EPIDOS
prospective study. Lancet 1996;348:511-514. |
|
Bauer DC, et al. Broadband ultrasound attenuation predicts fractures strongly
and independently of densitometry in older women. Arch Intern Med 1997;157:629-634. |
|
Hodson J, Marsh J. Quantitative ultrasound and risk factor enquiry as predictors
of postmenopausal osteoporosis: comparative study in primary care. BMJ 2003;326:1250-1251. |
|
|
|